Mp38-08 Sirt7 Expression Predicts Poor Prognosis in Upper Tract Urothelial Carcinoma Undergoing Postoperative Platinum-Based Adjuvant Chemotherapy

You have accessJournal of UrologyBladder Cancer: Upper Tract Transitional Cell Carcinoma II (MP38)1 May 2024MP38-08 SIRT7 EXPRESSION PREDICTS POOR PROGNOSIS IN UPPER TRACT UROTHELIAL CARCINOMA UNDERGOING POSTOPERATIVE PLATINUM-BASED ADJUVANT CHEMOTHERAPY Yudong Cao, Jinchao Ma, Shuo Wang, Xiao Yang, Yongpeng Ji, Ziyi Yu, Chen Lin, Yong Yang, and Peng Du Yudong CaoYudong Cao , Jinchao MaJinchao Ma , Shuo WangShuo Wang , Xiao YangXiao Yang , Yongpeng JiYongpeng Ji , Ziyi YuZiyi Yu , Chen LinChen Lin , Yong YangYong Yang , and Peng DuPeng Du View All Author Informationhttps://doi.org/10.1097/01.JU.0001008700.92603.b1.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Sirtuin 7 (SIRT7), a protein-coding gene implicated in carcinogenesis, has gained attention for its oncogenic properties and potential role in chemotherapy resistance. We aim to evaluate the expression of SIRT7 in UTUC as well as the predictive value for prognosis in patients undergoing radical nephroureterectomy followed platinum-based adjuvant chemotherapy. METHODS: Pathological samples of 94 UTUC with clinical stage T2 and above undergoing radical nephrectomy (RNU) were collected. All patients received adjuvant cisplatin-based chemotherapy and 38 UTUC patients received second-line immunotherapy after disease progression. The relationship between the expression level of SIRT7 by immunohistochemistry and clinicopathological characteristics, progression-free survival (PFS), overall survival (OS) and overall survival after progression (POS) was analyzed. RESULTS: Over a mean follow-up 36 months, 40 (42.6%) patients experienced recurrence and 24 (25.5%) patients died due to UTUC. The results revealed that 70.2% of UTUC tissue samples exhibited high expression levels of SIRT7. High expression of SIRT7 is associated with lymph node metastasis (p=0.011) and lymphovascular invasion (p=0.008). Moremore, UTUC patients with elevated SIRT7 expression experienced significantly shorter PFS hazard ratio (HR) 3.954, p=0.001 and OS (HR 3.477, p=0.025). Multivariate analyses demonstrated that SIRT7 served as a significant predictor for PFS (HR 2.586, p=0.036) in UTUC patients. Furthermore, SIRT7 high expression is associated with prolonged POS in patients progressed after chemotherapy and received second-line immunotherapy. CONCLUSIONS: SIRT7 is an independent prognostic marker of poor PFS in locally advanced UTUC patients undergone platinum-based adjuvant chemotherapy, and associated with prolonged POS in patients received second-line immunotherapy. These data suggest that SIRT7 could potentially serve as a target for assessing the efficacy of chemotherapy and immunotherapy in UTUC. Download PPT Source of Funding: Capital's Funds for Health Improvement and Research (2022-1G-1021) © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e643 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Yudong Cao More articles by this author Jinchao Ma More articles by this author Shuo Wang More articles by this author Xiao Yang More articles by this author Yongpeng Ji More articles by this author Ziyi Yu More articles by this author Chen Lin More articles by this author Yong Yang More articles by this author Peng Du More articles by this author Expand All Advertisement PDF downloadLoading ...